𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

✍ Scribed by Maurizia Rossana Brunetto; Francesco Moriconi; Ferruccio Bonino; George K. K. Lau; Patrizia Farci; Cihan Yurdaydin; Teerha Piratvisuth; Kangxian Luo; Yuming Wang; Stephanos Hadziyannis; Eva Wolf; Philip McCloud; Richard Batrla; Patrick Marcellin

Book ID
102850256
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
748 KB
Volume
49
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

Bristol-Myers Squibb, Gilead, and Novartis.

He is also in the speakers' bureau of Schering-Plough. Dr. Lau is on the speakers' bureau of and received grants from Roche and Novartis. Dr. Piratvisuth advises and is on the speakers' bureau of Roche. He advises Novartis and Schering-Plough and is on the speaker's bureau of GlaxoSmith Kline. Dr. Hadziyannis is on the speakers' bureau of and received grants from Roche. He advises and received grants from Gilead. He advises Novartis and Bristol-Myers Squibb. Dr. McCloud owns stock in Roche.

πŸ“œ SIMILAR VOLUMES

Prediction of sustained response to pegi
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 231 KB πŸ‘ 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic

Early on-treatment prediction of respons
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.